Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2019 Jan-Dec:18:2325958219848848.
doi: 10.1177/2325958219848848.

A Randomized Study of Passive versus Active PrEP Patient Navigation for a Heterogeneous Population at Risk for HIV in South Florida

Susanne Doblecki-Lewis  1 , Stefani Butts  1 , Valeria Botero  1 , Katherine Klose  1 , Gabriel Cardenas  2 , Daniel Feaster  2
Affiliations
Randomized Controlled Trial

A Randomized Study of Passive versus Active PrEP Patient Navigation for a Heterogeneous Population at Risk for HIV in South Florida

Susanne Doblecki-Lewis et al. J Int Assoc Provid AIDS Care. 2019 Jan-Dec.

Abstract

Effective approaches to promoting pre-exposure prophylaxis (PrEP) and linkage to PrEP care among those who may benefit the most from PrEP has proven to be a major challenge. We designed and pilot tested a strengths-based case management (SBCM) intervention for PrEP linkage. Adults interested in PrEP and meeting criteria (n = 61) were randomized to passive referral (control) or active SBCM (treatment). Outcomes measured were completion of provider visit, initiation of PrEP, and time to initiation of PrEP. Overall, 34% initiated PrEP by 12 weeks: 9 (29%) in the control group and 12 (40%) in the treatment group. The mean time to PrEP initiation was 13.1 weeks (95% confidence interval, 12.0-14.2) with no difference between groups ( P = .382). There was a 21% difference in achieving a provider visit between the treatment and control groups (53.3% versus 32.3%) by 12 weeks ( P = .096). Participants encountered financial, logistical, social, and provider-related barriers to PrEP access. Strengths-based case management-based patient navigation is a promising strategy for assisting PrEP seekers in obtaining a medical provider visit and initiating PrEP.

Keywords: HIV prevention; access to care; navigation; pre-exposure prophylaxis.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting Interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr. Doblecki-Lewis has served as on a scientific advisory board for Gilead Sciences.

Figures

Figure 1.
Figure 1.
CONSORT 2010 flow diagram.
Figure 2.
Figure 2.
Kaplan-Meier time-to-event analysis for receipt of pre-exposure prophylaxis (PrEP) medication, by study treatment group.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. McCormack S, Dunn DT, Desai M, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387(10013):53–60. - PMC - PubMed
    1. Molina J-M, Capitant C, Spire B, et al. On demand PrEP with oral TDF-FTC in MSM: results of the ANRS Ipergay trial. In: Conference on Retroviruses and Opportunistic Infections 2015.
    1. Sagaon-Teyssier L, Suzan-Monti M, Demoulin B, et al. , Uptake of PrEP and condom and sexual risk behavior among MSM during the ANRS IPERGAY trial. AIDS care. 2016;28(sup1):48–55. - PMC - PubMed
    1. Center for Disease Control and Prevention. Diagnoses of HIV infection and AIDS in the United States and dependent areas, 2009. HIV Surveillance Report. 2011;21:1–79.
    1. Cohen S.E, Vittinghoff E, Bacon O, et al. High interest in pre-exposure prophylaxis among men who have sex with men at risk for HIV-infection: baseline data from the US PrEP demonstration project. J Acquir Immune Defic Syndr. 2015;68(4):439. - PMC - PubMed

Publication types

MeSH terms

Substances